Dendritic cells treated with vasoactive intestinal peptide (VIP) reduced arthritis severity and bone erosion in mice with collagen-induced arthritis, performing as well as cells treated with a chemical immune suppressant.
Bone erosion reducedVIP-trained dendritic cells significantly reduced bone erosion in arthritic mice (P<0.05), potentially offering better bone protection than chemical alternatives
What the researchers found
VIP-treated dendritic cells (VIP-DC) showed reduced expression of immune activation markers (MHC II, CD40, CD86), decreased interferon-gamma production, and increased IL-4 production compared to untreated dendritic cells (P < 0.05 or 0.01).
When administered to mice with established collagen-induced arthritis, VIP-DC decreased clinical arthritis scores and reduced both bone erosion (P < 0.05) and inflammation (P < 0.01) compared to untreated dendritic cells. VIP-DC performed comparably to Bay 11-7082-induced tolerogenic dendritic cells but showed potentially superior bone protection.
Why it matters
Rheumatoid arthritis treatments often suppress the entire immune system, increasing infection risk. This study explores a more targeted approach — using a natural peptide (VIP) to reprogram specific immune cells into anti-inflammatory agents that can be delivered as a cell therapy. If translatable to humans, this could provide joint protection with fewer systemic side effects than current immunosuppressive drugs.
How the study worked
Mouse bone marrow cells were differentiated into dendritic cells using GM-CSF and IL-4, then treated with either VIP (40 ng/mL) or Bay 11-7082 (0.5 μg/mL) to induce tolerance. Cell surface markers and cytokine production were measured by flow cytometry and ELISA. The tolerogenic dendritic cells were then injected intraperitoneally into DBA mice with collagen-induced arthritis on day 40 (after arthritis onset). Treatment effects were assessed by clinical arthritis scoring and pathological examination of synovial hyperplasia, pannus formation, inflammation, and bone erosion.
What this study cannot tell us
This is an animal study using the collagen-induced arthritis model in mice, which doesn't perfectly replicate human rheumatoid arthritis. The study examined treatment started after arthritis onset, but follow-up duration and long-term outcomes were not detailed. The mechanism by which VIP-DC protect bone more effectively than Bay-DC was not fully elucidated. Sample sizes for the mouse experiments were not specified in the abstract.
How to read the evidence
This is a preclinical animal study using a standard mouse model of rheumatoid arthritis. While well-controlled with appropriate comparisons (untreated DC and Bay-DC), results need validation in human studies before clinical applicability can be assessed.
When this study was published
Published in 2019 in the International Journal of Rheumatic Diseases. The findings are part of a growing body of research on tolerogenic dendritic cell therapies, some of which have since entered early human trials for autoimmune diseases.
The bigger picture
Tolerogenic dendritic cell therapy is an emerging approach for autoimmune diseases — using the patient's own immune cells, reprogrammed to suppress rather than amplify inflammation. VIP is a naturally occurring 28-amino-acid peptide with known anti-inflammatory properties. This study adds to the evidence that VIP can effectively generate these therapeutic immune cells, potentially opening a path toward peptide-guided cell therapies for rheumatoid arthritis and other autoimmune conditions.
Questions still open
- Could VIP-treated dendritic cells from a patient's own blood be used as a cell therapy for rheumatoid arthritis?
- How long does the anti-arthritic effect of a single VIP-DC injection last?
- Would combining VIP-DC therapy with existing disease-modifying drugs produce better outcomes than either alone?
Common questions
What is VIP and how does it affect immune cells?
Could this become a treatment for human rheumatoid arthritis?
Read the original research
Vasoactive intestinal peptide-induced tolerogenic dendritic cells attenuated arthritis in experimental collagen-induced arthritic mice.
International journal of rheumatic diseases, 22(7), 1255-1262
Citation
Wu, Huaxiang; Shen, Jingfang; Liu, Lei; Lu, Xiaoyong; Xue, Jing. (2019). Vasoactive intestinal peptide-induced tolerogenic dendritic cells attenuated arthritis in experimental collagen-induced arthritic mice.. International journal of rheumatic diseases, 22(7), 1255-1262. https://doi.org/10.1111/1756-185X.13578